SBI-0640756

SKU: orb1302028

Description

SBI-756 is a novel, first-in-class small molecule inhibitor that selectively targets eIF4G1 to disrupt the eIF4F complex assembly. This mechanism has shown utility in preclinical cancer research, where it inhibits cap-dependent translation and demonstrates anti-proliferative effects in various in vitro cell-based assays.

Research Area

Cell Biology

Key Properties

• CAS Number: 1821280-29-8
• MW: 404.82
• Purity: 99.75%
• Formula: C₂₃H₁₄ClFN₂O₂
• SMILES: Fc1cncc(\C=C\C(=O)c2c(-c3ccccc3)c3cc(Cl)ccc3[nH]c2=O)c1
• Target: Autophagy,PERK
• Solubility: H2O:Insoluble;DMSO:50 mg/mL (123.51 mM)

Bioactivity

• In Vivo:
  Administration of SBI-0640756 only, starting 11 weeks after genetic inactivation of Ink4a and induction of NRasQ61E (about 10–14 days prior to tumor appearance), delayed tumor onset (from 20–26 weeks) and reduced tumor incidence, by 50%, compared with the control non-treated group. The growth of established tumors was largely inhibited by treatment with either BRAFi alone or a combination of BRAFi plus SBI-0640756.
• In Vitro:
  SBI-0640756 effectively dissociated eIF4G1 from the eIF4E in a dose-dependent manner, which was accompanied by a concomitant increase in 4E-BP1:eIF4E binding, reflective of impaired eIF4F complex formation. SBI-0640756 also inhibits the AKT/mTORC1 signaling and mTORC1 inhibition disrupts the eIF4F complex via activation of 4E-BPs. Whereas torin1 induced dissociation of eIF4G1 from eIF4E in WT but not in 4E-BP DKO MEFs, SBI-0640756 reduced eIF4G1:eIF4E association in both WT and 4E-BP DKO MEFs. Likewise, SBI-0640756 but not torin1 attenuated the proliferation of E1A/RAS-transformed 4E-BP DKO MEFs.
• Cell Research:
  Cells were rinsed with PBS and lysed as previously described. Protein concentration was determined using Coomassie Plus Protein Assay Reagent. Equal amounts of cell lysate proteins (50 μg) were separated on SDS-PAGE and transferred to polyvinylidene difluoride membranes. Membranes were blocked (5% BSA/TBST, 1 h) and incubated with primary antibodies (1 h at room temperate or overnight at 4°C), with shaking. Following three TBST washes, membranes were incubated for 1 h at room temperature secondary antibodies (1:10,000). Detection and quantifications were made using Odyssey Infrared Imaging System, or by exposing them to X-ray film. Antibodies against p-AKT, p-PRAS40, p-IKK, p-IκB, p-TSC, p-mTOR, p-p70S6K, p-RPS6, p-4E-BP1, pSGK3, AKT, PRAS40, IKK, IκB, mTOR, p70S6K, RPS6, 4E-BP1, GSK3, eIF4G1, and eIF4E were purchased from Cell Signaling Technology. Antibodies against β-actin and α-tubulin were obtained from Santa Cruz Biotechnology. Secondary antibodies were goat anti-rabbit Alexa-680 F(ab')2 and goat anti-mouse IRDye 800 F(ab')2. All antibodies were used according to the suppliers' recommendations.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, Inhibitor, Eukaryotic Initiation Factor (eIF), eIF-4G, Autophagy, SBI 0640756, SBI0640756, SBI-0640756, SBI 756, SBI756, SBI-756

Compound Identifiers

PubChem CID

121241171